Peter Blume-Jensen - Nov 14, 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen
Stock symbol
ACRV
Transactions as of
Nov 14, 2024
Transactions value $
-$477,228
Form type
4
Date filed
11/18/2024, 04:26 PM
Previous filing
Aug 23, 2024
Next filing
Nov 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability -$473K -59.8K -2.47% $7.92 2.36M Nov 14, 2024 Direct F1, F2
transaction ACRV Common Stock Tax liability -$3.88K -490 -0.15% $7.92 317K Nov 14, 2024 See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3 These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.